Beijing has announced the introduction of a ‘white list’ system to facilitate the import of items essential for drug research and development (R&D) by companies operating within the city. This initiative is outlined in the “Beijing Biomedical Research and Development Items Import Pilot Plan,” jointly released by multiple municipal authorities, including the Beijing Municipal Medical Products Administration and the Beijing Municipal Science & Technology Commission.
Pilot Plan Details
The Pilot Plan establishes a “white list” system specifically for the importation of items required by biomedical companies and R&D institutions registered in designated areas of Beijing, including Haidian District, Changping District, Daxing District, and the Beijing Economic-Technological Development Area. The white list includes items used during preclinical research, process materials, and auxiliary materials essential for R&D activities.
Application and Customs Procedures
Eligible companies can submit applications for white list imports through the local science and technology department. Once included on the white list, these companies can expedite customs clearance procedures at Beijing Customs without submitting the “Imported Drug Customs Clearance” form upon arrival at the Beijing port. The pilot plan has a duration of two years, with violations resulting in the revocation of pilot status and a two-year ban on white list applications.-Fineline Info & Tech
